Abstract Genomic alterations are commonly found in the signaling pathways of fibroblast growth factor receptors (FGFRs). Although there is no selective FGFR inhibitors in market, several promising inhibitors have been investigated in clinical trials, and showed encouraging efficacies in patients. By designing a hybrid between the FGFR-selectivity-enhancing motif dimethoxybenzene group and our previously identified novel scaffold, we discovered a new series of potent FGFR inhibitors, with the best one showing sub-nanomolar enzymatic activity. After several round of optimization and with the solved crystal structure, detailed structure-activity relationship was elaborated. Together with in vitro metabolic stability tests and in vivo pharmacokinetic profiling, a representative compound (35) was selected and tested in xenograft mouse model, and the result demonstrated that inhibitor 35 was effective against tumors with FGFR genetic alterations, exhibiting potential for further development.
Phenotypic and genetic alternations associated with tumorigenesis were gradually uncovered by large scale applications of gene sequencing and proteomics approaches [1] [2] [3] . Along with these genomics-wide studies, we have witnessed the spurt of kinase inhibitors developed for targeted cancer treatment. Currently, more than 38 kinase drugs were approved by U.S. Food and Drug Administration (FDA), and most of them are targeting receptor tyrosine kinases [4] [5] [6] . However, cancer is a complex neoplasia, processing extensive phenotypic heterogeneity and numerous genetic and transcriptional variations [7] [8] [9] [10] . Therefore, continuous efforts are needed to develop novel drugs as precision medicine for cancer patients.
Over the last years, the signaling pathways initialized by fibroblast growth factors (FGFs) are found to be important for progression and development of several cancers [11] [12] [13] [14] . To the best of our knowledge, currently 18 FGFs are identified in human genome, which regulated by four transmembrane FGF receptors to transduce the signal to intracellular components. FGFRs belong to the receptor tyrosine kinase family, and each composes of three extracellular immunoglobin type domains and intracellular kinase domain. Canonically, once the ligand bind to FGFR causes the dimerization and autophsphorylation, and activation. Helsten et al. 15 analyzed frequencies of FGFR aberrations in 4853 solid tumors with next-generation sequencing, revealing that 7.1% of all tumor types have genetic alterations in the FGF-FGFR axis, among them 49% affects FGFR1, 19% affects FGFR2 and 23% affects FGFR3 15 . This, along with other evidences 16, 17 , reinforces that the FGFRs are promising targets for many types of cancer disease.
Currently, the FGFR small-molecule inhibitors all targeted the ATP binding site in kinase domain, and are roughly classified into two types, non-selective FGFR inhibitors and selective FGFR inhibitors 18 . As exemplified in Fig. 1 , non-selective FGFR inhibitors are type-II kinase inhibitors, and usually associated with multi-kinase inhibitory activities, such as ponatinib which harbors potent activities at least for BCR-ABL, PDGFR, FGFR, VEGFR, and c-Src 19 . However, recent trend focused on developing selective FGFR inhibitors that are thought to have better safety window, and two most advanced drug candidates are illustrated in Fig. 1 20 . AZD4547, a potent FGFR1-3 inhibitor 21 , showed strong inhibition on the FGFR downstream pathway and cytotoxic effects on multiple cell lines, including NSCLC cells with FGFR1 amplification, gastric cancer (GC) cells carrying the FGFR2 amplification and endometrial cell line harboring the FGFR2-K310R/N550K mutations. Appealing clinical trial data from phase II proof-of-concept study also indicated its efficacy in patients with FGFR2 amplified GC (RR 33%), enabling the candidate advanced to phase III. Similarly, ARQ-087 22 , an oral pan-FGFR inhibitor, is also in phase III study, holding the promise for the treatment of patients with FGFR alterations.
In the present study, we reported our continuous effort on developing potent and selective FGFR inhibitors. Based on previous discoveries 23 , we found 5-hydrosulfonyl-5H-pyrrolo [2,3-b] pyrazine (4) was an intriguing scaffold for FGFR inhibitors, as it can be used to install two parts of chemical groups, one for the back-pocket and another for the ribose pocket. And both of them are considered to be essential for selectivity. With the guidance of structure analysis, we rapidly optimized the enzymatic activity of this series to about 10 nmol/L. However, the poor in vitro metabolic stability of compounds in liver microsome and high P450 inhibition hinder the further evaluation. Based on the solved crystal structure and metabolite identification, we carried out the optimization and finally obtained inhibitor 35 through the in vivo pharmacokinetic study as the promising FGFR inhibitor. Further in vivo pharmacological study confirmed the utility of the compound.
Results and discussion

Ligand design with hybrid approach
Based on our previous reported scaffold (5-hydrosulfonyl-5H-pyrrolo [2,3-b] pyrazine), we firstly carried out the structure-based binding mode analysis by superimposing cocrystal structure containing this scaffold (PDB 5Z0S) 23 and cocrystal structure AZD4547 (PDB 4V05) 24 . Clearly, based on the hybrid idea, we can substitute the pyrazole with two carbon linker and dimethoxybenzene group, which will extend into back pocket to make more favorable van der Waals interactions with the surrounding residues, thus increasing the binding affinity. Since in crystal structure 5Z0S the 6-chloroimidazo [1,2-b] pyridazine group forms a π-π stacking interaction with residue Phe489, we intended to preserve this interaction but to simplify the synthesis. Therefore, a synthesis-accessible benzene group was used to quickly test the hypothesis about the substitution with dimethoxybenzene group.
As listed in Table 1 , compound 5 showed about 75% inhibition ratio at 0.1 μmol/L, indicating the dimethoxybenzene is a better option for optimization. Dichloro substitution on the dimethoxybenzene (7) further increased the inhibitory activity to 14 nmol/L. Interestingly, modifying the linker can influence the binding activity: changing a carbon to nitrogen decreased the binding Figure 1 Representative FGFR inhibitors used in clinical trials (1) (2) (3) and our previous reported FGFR inhibitor (4) . activity; using ethylene rigidifies the linker can retain the activity, while using the acetylene decreased the activity about 10 folds.
Optimization of imidazole part
After confirming dimethoxybenzene is a suitable back-pocket binding motif, we proceeded to optimize the π-π stacking group. As shown in Table 2 , substitution with cyclopentane ring (10) reduced the binding activity, which supports that it needs an aromatic ring system to participate in the π-π stacking. Generally, comparing bicyclic compounds (17) (18) (19) , we found that monocyclic aromatic compounds showed better binding activities. However, compounds substituted with electron-deficient ring (11) or electron-rich ring (12) displayed similar binding activities, indicating the electron property is not a relevant factor for the binding. Comparing compounds 15 and 16, we can realize that compounds substituted at para-position of benzene group generate more potent inhibitors.
To verify the binding mode of this series of inhibitors, we conducted crystallization of FGFR2 with compound 14. As illustrated in Fig. 2B , the dimethoxybenzene group situated in the back pocket, making van der Waals interactions with surrounding residues Met538, Val564 and Phe645 and the imidazole positioned above the pyrrolopyrazine scaffold. However, different from the prediction, the imidazole did not form π-π stacking with the protein. Besides, we found the A-loop of FGFR2 kinase domain was disordered in current crystal structure. Whether this discrepancy is due to the difference between FGFR1 and FGFR2 or is due to different ligands still needs further investigation. The ethyl acetate substitution on the imidazole group oriented into the back pocket, making a weak hydrogen bonding interaction with the backbone of residue Asp644 (the distance between heavy atoms is 3.2 Å).
Based on the solved crystal structure (5Z0S), we speculated that the imidazole of compound 12 would be facing the interior part of the binding site. Therefore, it may provide new direction for next round optimization. The inhibitory activity of compound 14 further strengthened this hypothesis. Then, we selected compound 12 to check its metabolic stability, as it represents the simple starting point for further optimization. As listed in Table 4 , this compound showed good stability in human microsome. But from the CYP450 inhibition assay, it turned out to be a potent inhibitor for five isotype CYP450 enzymes, indicative of a potential drug-drug interaction risk, which makes us to perform further optimization.
Based on the solved crystal structure of 14, we decided to focus on the imidazole part, as it has large room for modification. As shown in Table 3 , compounds with various substitutions on imidazole ring were prepared and several of them showed excellent inhibitory activities towards FGFR1 enzymatic assay and FGFR1-amplification KG1 cellular assay. Detailed analysis identified that the smaller the substituents the higher the inhibitory activity. For example, compounds 20 and 21 with small substituents exhibited single digit nanomolar activity. While several bulky substituents (25) (26) (27) (28) showed much lower inhibitions, which may clash with surrounding residues and reduce the binding affinity. We also synthesized compound 29 containing 1,5-dichloro-2,4-dimethoxybenzene to check the binding affinity. The result indicated it is a very potent FGFR1 inhibitor, with the enzymatic IC 50 value in the picomolar range. We also tested the antiproliferative activity of these compounds in KG1 cellular context. In consistent with the enzymatic assay, compounds with smaller substituents showed great antiproliferative inhibition. However, compound 29 did not present highest cellular activity, which may be due to the compound is more hydrophilic than other analogues (20) (21) (22) . Therefore, it is detrimental to the membrane permeability.
Optimization of metabolic stability
We selected three potent inhibitors to check the metabolic stability.
As listed in Table 4 , similar to compound 12, compound 29 still showed high inhibition towards five CYP450 enzymes. However, the substituted imidazole compounds appear reduced inhibitory activities on CYPs, and only the CYP450 3A4 was targeted with about 90% inhibition ratio at 10 μmol/L concentration. To find out the metabolic liable site of the inhibitors, we picked compound 21 to perform the metabolite identification. The result demonstrated that demethylation at dimethoxybenzene ring is the main factor contributing to the metabolism of this compound in human liver microsome (Supporting Information Fig. S1 ). Consequently, the next round of optimization focused on the dimethoxybenzene ring. To reduce the rate of demethylation, two approaches were adopted. The first is to modify the methoxyl group by extending to ethyl (30) or cyclizing (31). However, the inhibitory activity decreased dramatically. It is known that electron-rich chacteristics will enable the P450 enzyme to accelerate the metabolic catalysis. Thus, the second approach is to reduce the electron density of dimethoxybenzene by adding the fluorine atom (32), which slightly increased the IC 50 activity to 0.4 nmol/L. We further prepared three analogues by changing the substituents on imidazole (33) and modifying the linker to ethylene to further rigidify the compounds (34 and 35). The three compounds showed equipotent enzymatic activity as compound 32. The antiproliferative inhibition on KG1 cell line of these four fluorine substituents were also listed in Table 5 , demonstrating high potency as FGFR1 inhibitors.
In order to verify the utility of this series of FGFR inhibitors, compound 35 was selected for metabolic stability test, as it processing excellent potency, lower electron density on dimethoxybenzene moiety and possibly stabilized fluoroethyl substituted imidazole ring. As shown in Table 4 , compound 35 demonstrated much lower inhibition ratio for five selected CYPs than previous tested compounds.
Before investigating the antitumor activity of compound 35, we selected 12 typical RTKs to assess its kinase selectivity. The data (Supporting Information Table S2 ) showed that compound 35 has negligible inhibition on these kinases, indicating compound 35 is a selective FGFR inhibitor. We also inspected the pharmacokinetic properties of compound 35 in mice. Three CD-1 mice were dosed with 10 mg/kg of 35 via intragastric administration. From the calculated PK parameters, it was found the compound has moderate plasma exposure (AUC 434 ng Á h/mL) and half-life of 1.9 h. Given the maximum drug concentration in plasma of about 342 ng/mL and lipophilic characteristics of 35, we speculated the compound may have good tissue distribution. We continued the in vivo pharmacological study to check the antitumor effect of 35.
In vivo antitumor efficacy of compound 35
We assessed the in vivo efficacies of 35 on model with FGFR alterations. Mice bearing xenograft tumors derived from SNU-16 cells (this cell line is FGFR2-amplified, and IC 50 of compound 35 against this cell line is 74.8 nmol/L), as the representative model, was treated orally with 35 once daily for 21 consecutive days. As illustrated in Fig. 3 , 35 suppressed the tumor growth at a dose of 10 mg/kg in the SNU-16 model (Fig. 3A) . No severe weight loss was observed during the treatment (Fig. 3B) . These results demonstrated that inhibitor 35 was effective against tumors with FGFR genetic alterations, exhibiting potential for further study.
Chemistry
Compounds 5-7 and 10-29 were prepared according to Scheme 1. Sonogashira coupling of 36 with TMSA provided 37. Intramolecular ring of 37 produced 38. Treatment of 38 with benzenesulfonyl chloride afforded 39, and Buchwald-Hartwig coupling reaction with corresponding amine was used to generate 6. 9. Treatment of 51 with sulfuryl dichloride afforded 52. Compound 53 was prepared by Wittig reaction of 52, and Heck coupling conditions were used to generate 8. Sonogashira coupling of 38 provided 54a and 54b. Compounds 54a and 54b were reduced and sulfonylated to afford 30 and 31.
Compounds 32-35 were synthesized according to the procedures in Scheme 3. Compound 56 was generated by the removal of silicon protection of 48. Treatment of 56 with Selectflour afforded 57 and 58. Sonogashira coupling of 38 provided 59. Compound 59 was reduced and sulfonylated to afford 32. Compound 38 was sulfonylated to afford 61 and 63. Sonogashira coupling of 61 afforded 62. Compound 34 was synthesized by reduction. Compound 64 was provided by substitution of 63, and Sonogashira coupling conditions were used to provide 65 and 66. Compounds 33 and 35 were prepared by reduction.
Conclusions
Aberrant signaling of FGF-FGFR axis was identified in many types of human cancers, which stimulates extensive efforts to develop inhibitors targeting the FGFR, a subfamily of receptor tyrosine kinases. Based on No inhibition -, not tested. a Human liver microsomal intrinsic clearance (μL/min Á mg). b CYPs direct inhibition, sometimes referred to reversible inhibition, is assessed by measurement of an enzyme (CYP) activity in the presence of increasing concentration of inhibitor without a pre-incubation step.
c TDI stands for time-dependent inhibition, which is referring to a change in enzyme inhibition during an in vitro incubation and means an irreversible inactivation of CYPs. The k obs value lower than 200 (unit: 10 -4 /min) was considered to be no TDI inhibition.
the hybrid approach and structure-based design, we combined a novel scaffold and a well-known FGFR-selectivity enhancing motif to quickly optimize the enzymatic activity to nmol/L range. With considerable efforts to improve the drug-like properties, we finally acquired resistance to the kinase inhibitors make it inevitable to develop new chemotype inhibitors. Giving the novel binding mode of present disclosed FGFR inhibitors, it would be interesting to see whether it will have different utility in profiling the landscape of mutations of FGFRs, or it will play a different role in treating the acquired resistance coming along with other FGFR inhibitors.
Materials and methods
General methods of chemistry
1 H NMR (400 MHz) spectra were recorded by using a Varian Mercury-400 high performance digital FT-NMR spectrometer (Varian, Palo Alto, USA) with tetramethylsilane (TMS) as an internal standard. 13 C NMR (100 or 125 MHz) spectra were recorded by using a Varian Mercury-400 high performance digital FT-NMR spectrometer (Varian, Palo Alto, USA) or Varian Mercury-500 high performance digital FT-NMR spectrometer (Varian, Palo Alto, USA). Abbreviations for peak patterns in NMR spectra are the following: br ¼ broad, s ¼ singlet, d ¼ doublet, and m ¼ multiplet. Low-resolution mass spectra were obtained with a Finnigan LCQ Deca XP mass spectrometer (ThermoFinnigan, Santa Clara County, USA) using a CAPCELL PAK C18 (50 mm Â 2.0 mm, 5 μm) or an Agilent ZORBAX Eclipse XDB C18 (50 mm Â 2.1 mm, 5 μm) (Agilent, Santa Clara County, USA) in positive or negative electrospray mode. Low-resolution mass spectra and high-resolution mass spectra were recorded at an ionizing voltage of 70 eV on a Finnigan/ MAT95 spectrometer (ThermoFinnigan, Santa Clara County, USA). High resolution mass spectra were recorded by using a Finnigan MAT-95 mass spectrometer (ThermoFinnigan, Santa Clara County, USA) or an Agilent technologies 6224 TOF mass spectrometer (Agilent, Santa Clara County, USA). Purity of all compounds was determined by analytical Gilson high performance-liquid chromatography (HP-LC) using an YMC ODS3 column (50 mm Â 4.6 mm, 5 μm). Conditions were as follows: CH 3 CN/H 2 O eluent at 2.5 mL/min flow [containing 0.1% trifluoroacetic acid (TFA)] at 35 1C, 8 min, gradient 5% CH 3 CN to 95% CH 3 CN, monitored by UV absorption at 214 and 254 nm. TLC analysis was carried out with glass precoated silica gel GF254 plates. TLC spots were visualized under UV light (SCRC, Shanghai, China). Flash column chromatography was performed with a Teledyne ISCO CombiFlash Rf system (Teledyne, Santa Clara County, USA). All solvents and reagents were used directly as obtained commercially unless otherwise noted. Anhydrous dimethylformamide was purchased from Acros (InnoChem, Beijing, China) and was used without further drying. All air and moisture sensitive reactions were carried out under an atmosphere of dry argon with heat-dried glassware and standard syringe techniques. Microwave reactions were performed with Biotage initiator focused beam microwave reactor (400 W, Biotage, Stockholm, Biotage).
The synthesis of details of target compounds
4.2.1. 6-Bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine (37) 3,6-Dibromopyrazin-2-amine (36, 5 g, 19.8 mmol), TMSA (2.14 g, 21.8 mmol), Pd(PPh 3 ) 2 Cl 2 (1.15 g, 0.99 mmol), CuI (189 mg, 0.99 mmol) and triethylamine (4 g, 39.6 mmol) were dissolved in THF and the resultant solution was purged with argon. The reaction mixture was cooled to 0 1C and stirred for 1H. And then the reaction was left to warm up to room temperature for another 8 h. Then water was added to the reaction system. The reaction mixture was extracted with ethyl acetate. The organic phase was concentrated under reduced pressure to give the crude target product, which was purified by flash column chromatography with dichloromethane/methanol to afford compound [2,3-b] pyrazine (38) 6-Bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine (37, 3g, 11 mmol) was dissolved in anhydrous DMF and the mixture was cooled to 0 1C. Potassium t-butoxide (2.5 g, 22 mmol) was slowly added to the above solution. Then the mixture was stirred for 4 h at 0 1C. Subsequently, the reaction was stirred for another 20 h at room temperature. After the reaction finished (monitored by TLC), water was added. The mixture was extracted three times with ethyl acetate, washed with ammonium chloride and dried over sodium sulfate, concentrated, and purified by column chromatography to give compound 38 as yellow solid with the yield of 62%. [2,3-b] pyrazine (38, 100 mg, 0.5 mmol) and NaH (13 mg, 0.55 mmol) were dissolved in anhydrous DMF. After the reaction mixture was stirred at 0 1C for 10 min. Benzenesulfonyl chloride (75 μL, 0.55 mmol) dissolved in 5 mL of anhydrous DMF was slowly added in drops, and the mixture was stirred for 1H at room temperature. The resulting solution was poured into H 2 O and extracted with CH 2 Cl 2 . The organic layer was washed with brine and dried with Na 2 SO 4 . The organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 39 as white solid with the yield of 88%. 1 [2,3-b] pyrazine (39, 100 mg, 0.296 mmol), 3,5-dimethoxybenzylamine (49 μL, 0.325 mmol), BINAP (18 mg, 0.03 mmol) and Cs 2 CO 3 (193 mg, 0.59 mmol) were dissolved in methylbenzene in a microwave tube was flushed with N 2 for 5 min, then Pd 2 (DBA) 3 (27 mg, 0.03 mmol) was added and the reaction was degassed again for further 5 min. The resulting mixture was stirred at 100 1C for 3 h. Then the reaction mixture was evaporated to dryness. The residue was purified by flash chromatography to give 6 as gray solid with the yield of 70%. 
3-Bromo-5H-pyrrolo
4.2.3. 3-Bromo-5-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazine (39) 3-Bromo-5H-pyrroloH NMR (400 MHz, chloroform-d) δ 8.61 (s, 1H), 8.24 (dd, J ¼ 8.5, 1.3 Hz, 2H), 7.99 (d, J ¼ 4.1Hz, 1H), 7.71-7.64 (m, 1H), 7.62-7.55 (m, 2H), 6.83 (d, J ¼ 4.1Hz, 1H). 4.2.4. N-(3,5-Dimethoxybenzyl)-5-(phenylsulfonyl)-5H-pyrrolo [2,3-b]pyrazin-3-amine (6) 3-Bromo-5-(phenylsulfonyl)-5H-pyrrolo4.2.6. 3-(3,5-Dimethoxyphenethyl)-5H-pyrrolo[2,3-b]pyrazine (41) Hydrogen gas was applied (2 bar) onto a solution of 3-((3,5-dimethoxyphenyl)ethynyl)-5H-pyrrolo[2,3-b]pyrazine (40, 100 mg) and dry Pd-C (10 mg) in EtOH. Then the mixture was stirred for 4 h at 30 1C. After the reaction finished (monitored by TLC), the solid was separated by decantation and filtration. The liquid was concentrated under reduced pressure. The crude mixture was purified by flash column chromatography on silica gel to afford compound 41 as white solid with the yield of 92%.acetate. The organic layer was washed with brine and dried with Na
3-(2,6-Dichloro
85 mmol) and NaH (75 mg, 3.14 mmol) was dissolved in anhydrous DMF. After the reaction mixture was stirred at 0 1C for 10 min. 2-Nitrobenzenesulfonyl chloride (696 mg, 3.14 mmol) in anhydrous DMF was slowly added in drops, and the mixture was stirred for 30 min at room temperature. Then the resulting solution was poured into H 2 O and extracted with CH 2 Cl 2 . The organic layer was washed with brine and dried with Na 2 SO 4 . The organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 45 as yellow solid with the yield of 76%. 3 . After the reaction mixture was stirred at 110 1C for 8 h. After the reaction finished (monitored by TLC), the reaction mixture was evaporated to dryness. Then CH 2 Cl 2 was added. Then the organic layer was washed with ice water and dried with Na 2 SO 4 . The organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 69 as white solid with the yield of 54%. 
2,4-Dichloro-3-ethynyl-1,5-dimethoxybenzene (50)
TBAF/THF (2.9 ml, 2.9 mmol) was added to a solution of ((2,6-dichloro-3,5-dimethoxyphenyl)ethynyl)trimethylsilane (49, 800 mg, 2.6 mmol) in CH 2 Cl 2 , and the reaction mixture was stirred at room temperature for 1H. After the reaction finished (monitored by TLC), CH 2 Cl 2 was added. The organic phase was washed with water, and dried over Na 2 SO 4 . Then the organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 50 as white solid with the yield of 88%. 65 (s, 1H), 3.99 (s, 6H) ¼ 8.1Hz, 1H), 6.81 (s, 1H), 4.09 (q, J ¼ 6.9 Hz, 2H), 1.47 (t, J ¼ 6.9 Hz, 3H). Intermediate 54b was prepared with a similar procedure as used for 54a (see Scheme 2 and Supporting Information Section 5).
3-(3-Ethoxyphenethyl)-5H-pyrrolo[2,3-b]pyrazine (55a)
Hydrogen gas was applied (2 bar) onto a solution of 3-((3-ethoxyphenyl)ethynyl)-5H-pyrrolo [2,3-b] pyrazine (54a, 100 mg) and dry Pd-C (10 mg) in EtOH. Then the mixture was stirred for 4 h at 30 1C. After the reaction finished (monitored by TLC), the solid was separated by decantation and filtration. The liquid was concentrated under reduced pressure. The crude mixture was purified by flash column chromatography on silica gel to afford compound 55a as white solid with the yield of 82%. Intermediate 55b was prepared with a similar procedure as used for 55a (see Scheme 2 and Supporting Information). [2,3-b] pyrazine (55a, 50 mg, 0.19 mmol) and NaH (5 mg, 0.21 mmol) were dissolved in anhydrous DMF. After the reaction mixture was stirred at 0 1C for 10 min. 1-Methyl-1H-imidazole-4-sulfonyl chloride (38 mg, 0.21 mmol) in anhydrous DMF was slowly added in drops, and the mixture was stirred for 30 min at room temperature. Then the resulting solution was poured into H 2 O and extracted with CH 2 Cl 2 . The organic layer was washed with brine and dried with Na 2 SO 4 . The organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 30 as white solid with the yield of 76%. 
3-(3-Ethoxyphenethyl
)-5-((1-methyl-1H-imidazol-4-yl) sulfonyl)-5H-pyrrolo[2,3-b]pyrazine (30) 3-(3-Ethoxyphenethyl)-5H-pyrrolo
1-Ethynyl-3,5-dimethoxybenzene (56)
TBAF/THF (2.2 mL, 2.2 mmol) was added to a solution of ((3,5-dimethoxyphenyl)ethynyl)trimethylsilane (48, 500 mg, 2 mmol) in CH 2 Cl 2 , and the reaction mixture was stirred at room temperature for 1H. After the reaction finished (monitored by TLC), CH 2 Cl 2 was added. The organic phase was washed with water, and dried over Na 2 SO 4 . Then the organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 56 as white solid with the yield of 78%. After stirring for 20 h at room temperature, the solution was concentrated under reduced pressure and CH 2 Cl 2 was added. Then saturated NaHCO 3 solution was added, and the organic phase was washed with brine (100 mL), and dried over Na 2 SO 4 . Then the organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 57 as white solid with the yield of 50%. [2,3-b] pyrazine (60, 50 mg, 0.17 mmol) and NaH (5 mg, 0.19 mmol) was dissolved in anhydrous DMF. After the reaction mixture was stirred at 0 1C for 10 min. 1-Methyl-1H-imidazole-4-sulfonyl chloride (34 mg, 0.19 mmol) in 5 mL of anhydrous DMF was slowly added in drops, and the mixture was stirred for 30 min at room temperature. Then the resulting solution was poured into H 2 O and extracted with CH 2 Cl 2 . The organic layer was washed with brine and dried with Na 2 SO 4 . The organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography to afford 32 as white solid with the yield of 77%. After the reaction finished (monitored by TLC), the solution was filtered and evaporated to dryness. The residue was purified by flash chromatography to give 34 as yellow solid with the yield of 75%. 1 was prepared with a similar procedure as used for 33 (see Scheme 3 and Supporting Information).
3-(2-Fluoro
-3,5-dimethoxyphenethyl)-5-((1-methyl-1H- imidazol-4-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazine (32) 3-(2-Fluoro-3,5-dimethoxyphenethyl)-5H-pyrrolo4.2.39. 3-((2-Fluoro-3,5-dimethoxyphenyl)ethynyl)-5-((1-(2-fluo- roethyl)-1H-imidazol-4-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazine (65) A solution of 3-bromo-5-((1-(2-fluoroethyl)-1H-imidazol-4-yl)sul- fonyl)-5H-pyrrolo[2,
3-(
2-Fluoro-3,5-dimethoxyphenethyl)-5-((1-(2-fluoroethyl)- 1H-imidazol-4-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazine (33) A solution of 3-((2-fluoro-3,5-dimethoxyphenyl)ethynyl)-5-((1- (2-fluoroethyl)-1H-imidazol-4-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyra-
Protein expression, purification and X-ray crystallography
Human FGFR2-(461-768) A628T and E767Q mutation construct was cloned into a modified pET21b vector (Novagen, Malaysia) between BamHI and XhoI, which places expression under the control of the T7-lacO promoter. The protein was expressed in Escherichia coli BL21-Gold(DE3) cells (Stratagene, USA) as an N-terminal fusion to a hexahistidine affinity tag with integrated TEV protease site. A single colony was inoculated in LuriaBertani media containing 100 μg/mL ampicillin at 37 1C, 250 rpm until the A600 reached 0. The protein was loaded on a second Ni-NTA column equilibrated with lysis buffer. The untagged protein was eluted by the buffer containing 50 mmol/L Hepes, 200 mmol/L NaCl, 5% glycerol, 5 mmol/L B-ME and 10 mmol/L imidazole, pH 7.5. The purified protein was concentrated and further purified by an S200 column (GE Healthcare, USA) to get 95% purity as assessed by SDS-PAGE analysis stained by Coomassie Brilliant Blue R-250 and concentrated to 10 mg/mL in the 50 mmol/L Tris, 200 mmol/L NaCl, 5% glycerol, 5 mmol/L B-ME pH 7.5. For crystallization, 10 mg/mL protein was incubated compound for about 3 h and Mcompound:Mprotein is 5:1. The crystals of FGFR2/compound 14 were obtained within 2 days by hanging drop vapor diffusion method at 18 1C. The drop was composed of 1 μL of protein/compound mixture and 1 μL crystallization buffer of 0.2 mol/L ammonium sulfate, 0.1 mol/L MES pH 6.5 and 30% (w/v) PEG 5000 MME.
The FGFR2/compound 14 cocrystals were cryo-protected in mother liquor containing 20% glycerol and flash-frozen in liquid nitrogen. Diffraction data were collected at SSRF beamline BL19U1 and processed using HKL3000 25 . The molecular replacement software Phaser was used to solve the structure with a search model from PDB entry 4J95 26 . Iterative structure refinement and model building were performed between Refmac5 and Coot 27, 28 . Compounds were observed in the electron density map built into the structure model.
ELISA kinase assay
The effects of indicated compounds on the activities of FGFR1 kinase (Eurofins, San Francisco, USA) were determined using enzymelinked immunosorbent assays (ELISAs) with purified recombinant proteins. Briefly, 20 μg/mL poly (Glu, Tyr) 4:1 (Sigma, St Louis, MO, USA) was pre-coated in 96-well plates as a substrate. A 50 μL aliquot of 10 μmol/L ATP solution diluted in kinase reaction buffer (50 mmol/L HEPES [pH 7.4], 50 mmol/L MgCl 2 , 0.5 mmol/L MnCl 2 , 0.2 mmol/L Na 3 VO 4 , and 1 mmol/L DTT) was added to each well; 1 μL of various concentrations of indicated compounds diluted in 1% DMSO (v/v) (Sigma, St Louis, MO, USA) were then added to each reaction well. 1% DMSO (v/v) was used as the negative control. The kinase reaction was initiated by the addition of purified tyrosine kinase proteins diluted in 49 μL of kinase reaction buffer. After incubation for 60 min at 37 1C, the plate was washed three times with phosphate-buffered saline (PBS) containing 0.1% Tween 20 (T-PBS). Anti-phosphotyrosine (PY99) antibody (Cell Signaling Technology, Danvers, UK) (100 μL, 1:500, diluted in 5 mg/mL BSA T-PBS) was then added. After a 30 min incubation at 37 1C, the plate was washed three times, and 100 μL horseradish peroxidase-conjugated goat anti-mouse IgG (Cell Signaling Technology, Danvers, UK) (1:1000, diluted in 5 mg/mL BSA T-PBS) was added. The plate was then incubated at 37 1C for 30 min and washed 3 times. A 100 μL aliquot of a solution containing 0.03% H 2 O 2 and 2 mg/mL o-phenylenediamine in 0.1 mol/L citrate buffer (pH 5.5) was added. The reaction was terminated by the addition of 50 μL of 2 mol/L H 2 SO 4 as the color changed, and the plate was analyzed using a multi-well spectrophotometer (SpectraMAX190, from Molecular Devices, Palo Alto, CA, USA) at 490 nm. The inhibition rate (%) was calculated using the following equation: [1À (A 490 /A 490 control )] Â 100. The IC 50 values were calculated from the inhibition curves in two separate experiments.
Cell proliferation assay
Cell proliferation was examined in a FGFR1-translocated KG1 leukemia cell line harboring FGFR1OP-FGFR1 fusion. The original KG1 cell line was purchased from ATCC (CRL-8031) (ATCC, Manassas, USA), and cultured according the ATCC standard protocol. Cells were seeded in 96-well cell culture plates. On the day when seeding, the cells were exposed to various concentrations of compounds and further cultured for 72 h at 37 1C. Cell proliferation was then determined using Cell Counts Kit-8 (CCK8) assay (Dojindo Laboratories, Kumamoto, Japan). The IC 50 values were calculated by concentration-response curve fitting using the four-parameter method.
In vitro metabolic stability study
Microsomes (human microsome: Xenotech, Lot No.H0610; Rat microsome: Xenotech, Lot No. R1000 (XenoTech, USA) (0.5 mg/mL) were preincubated with 1 μmol/L of test compound for 5 min at 37 1C in 0.1 mol/L phosphate buffer (pH 7.4) with 1 mmol ethylenediaminetetraacetic acid (EDTA), and 5 mmol MgCl 2 . The reactions were initiated by adding prewarmed cofactors (1 mmol NADPH). After 0, 5, 10, and 30 min incubation at 37 1C, the reactions were stopped by adding an equal volume of cold acetonitrile. The samples were vortexed for 10 min, and then centrifuged at 10,000 Â g for 10 min. Supernatants were analyzed by LC-MS/MS for the amount of the remaining parent compound, and the corresponding loss of the parent compound was also determined by LC-MS/MS.
The cytochromes P450 (CYP) enzymatic activities were characterized based on their probe reactions: CYP3A4 (midazolam), CYP2D6 (dextromethorphan), CYP2C9 (diclofenac), CYP1A2
